Dr Lavinia Spain
Honorary Conjoint Senior Fellow
The Sir Peter MacCallum Department of Oncology
49 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32026
Journal article
CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.
DOI: 10.1200/JCO.2026.44.7_suppl.4162025
Journal article
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma
DOI: 10.1186/s13059-025-03812-22025
Journal article
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
DOI: 10.1136/jitc-2025-0118652025
Journal article
1694eP Real-world induction targeted therapy (TT) with immune checkpoint inhibitor (ICI) therapy switch in advanced BRAF-mutant melanoma: A multi-institutional study
DOI: 10.1016/j.annonc.2025.08.23212025
Journal article
Post-SRS haemorrhage and oncological outcome of patients with melanoma brain metastases undergoing stereotactic radiotherapy
DOI: 10.1007/s00066-025-02393-02025
Journal article
Neoadjuvant Pembrolizumab and Stereotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER): A Phase II Randomised Clinical Trial
DOI: 10.1016/j.ijrobp.2025.06.1178
RECENT SCHOLARLY WORKS
2025
Journal article
1636P Gonadal toxicity in men receiving immune checkpoint inhibitors for melanoma
DOI: 10.1016/j.annonc.2025.08.22642025
Journal article
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
DOI: 10.1038/s41591-025-03704-92025
Journal article
Patient-reported acute and chronic toxicities from adjuvant therapies post resection of melanoma.
DOI: 10.1200/jco.2025.43.16_suppl.e21568